Syros Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Syros Pharmaceuticals generated cash of -$109,707,000, which is more than the previous year. Cash used in financing activities reached the amount of $43,462,000 last year. Net change in cash is therefore -$28,908,000.
Cash Flow
| 2014 | -11.96M | -201K | 68.76M |
|---|---|---|---|
| 2015 | -23.03M | -1.17M | -278K |
| 2016 | -40.53M | -27.34M | 90.55M |
| 2017 | -44.72M | -15.59M | 33.93M |
| 2018 | -40.31M | -10.64M | 69.08M |
| 2019 | -60.25M | -11.73M | 65.99M |
| 2020 | -57.36M | 46.66M | 142.95M |
| 2021 | -99.54M | -52.65M | 70.51M |
| 2022 | -123.06M | 67.18M | 131.04M |
| 2023 | -109.70M | 37.33M | 43.46M |
SYRS Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 170.55M | 95.38M | 177.07M | 44.81M | 50.81M | 32.68M | 58.58M | 35.90M | 60.39M | 3.80M |
Operating activities | ||||||||||
Net income | -164.57M | -94.65M | -86.55M | -84.03M | -75.43M | -62.27M | -54.01M | -47.74M | -29.81M | -13.43M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 2.25M | 2.96M | 3.01M | 3.03M | 2.72M | 1.60M | 1.52M | 1.27M | 602K | 258K |
Stock-based compensation expense | 10.43M | 11.41M | 10.35M | 10.93M | 9.83M | 0 | 4.41M | 4.23M | 3.23M | 937K |
| Deferred income tax benefit | 10.43M | 11.41M | 10.35M | 10.93M | 9.83M | 0 | 4.41M | 4.23M | 3.23M | 937K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 1.69M | 1.28M | 7K | 19.99M | -20.15M | 0 | 867K | -317K | 0 | 0 |
Inventories | 0 | -1.28M | 1.98M | -2.53M | -4.35M | 0 | 3.29M | 2.69M | 0 | 0 |
Accounts payable | 5.13M | 2.76M | 48K | -1.05M | 1.49M | 888K | 141K | -404K | 2.02M | 334K |
Cash generated by operating activities | -109.70M | -123.06M | -99.54M | -57.36M | -60.25M | -40.31M | -44.72M | -40.53M | -23.03M | -11.96M |
Investing activities | ||||||||||
Purchases Of Investments | -50.96M | 0 | -51.40M | 0 | -108.20M | -96.76M | -41.77M | -25.02M | 0 | 0 |
Investments In Property Plant And Equipment | -272K | -1.24M | -1.24M | -3.33M | -12.63M | -1.38M | -821K | -2.32M | -1.17M | -201K |
Acquisitions Net | 0 | 0 | 0 | 0 | 110K | 9K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 37.33M | 67.18M | -52.65M | 46.66M | -11.73M | -10.64M | -15.59M | -27.34M | -1.17M | -201K |
Financing activities | ||||||||||
Common Stock Issued | 43.27M | 119.76M | 70.77M | 103.78M | 61.18M | 0 | 32.30M | 53.87M | -228K | 15K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -81K | 0 | 0 | 0 | 0 | 0 | 0 | -620K | 0 |
Repayments of term debt | -65K | -291K | -265K | -39.37M | -205K | -50K | -168K | -135K | -50K | 0 |
Cash used in financing activities | 43.46M | 131.04M | 70.51M | 142.95M | 65.99M | 69.08M | 33.93M | 90.55M | -278K | 68.76M |
Net Change In Cash | -28.90M | 75.16M | -81.68M | 132.25M | -5.99M | 18.12M | -26.38M | 22.67M | -24.48M | 56.59M |
Cash at end of period | 141.64M | 170.55M | 95.38M | 177.07M | 44.81M | 50.81M | 32.20M | 58.58M | 35.90M | 60.39M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |